Provenge's Approval, Which Had Been Forecasted By Decision Resources Nearly a Decade Ago Despite Skepticism, Marks a Crucial Turning Point in the Potential

of Therapeutic Vaccines in Oncology

The Decision Resources analyst call entitled TOLD YOU SO! Almost a Decade after Decision Resources First Forecasted Its Launch, Provenge is Approved: Will It Become a Blockbuster and Pave the Way for Other Cancer Vaccines? will be held at 10 a.m. U.S. eastern time on May 6, 2010.

Decision Resources Analyst Andrew Merron, Ph.D. is available now to speak to members of the media regarding last week's approval by the U.S. Food and Drug Administration of Dendreon's Provenge for the treatment of prostate cancer. Members of the media are also invited to attend this 15-minute analyst call, which will be presented by Dr. Merron on May 6.

Provenge's approval, which had been first forecasted by Decision Resources almost a decade ago, is a significant development in oncology as the agent is now the first therapeutic vaccine to be approved for any oncology indication within the world's seven major pharmaceutical markets.

The launch of Provenge heralds a new era in oncology treatment and represents a crucial turning point in the potential of therapeutic vaccines in oncology. Provenge, which significantly improves overall survival, will fulfill an urgent unmet need in this indication and the drug now carries the distinction of being the first approved individualized, targeted treatment for prostate cancer.

In this 15-minute analyst call, Dr. Merron will answer the following questions:

  --  What is Decision Resources' forecast for the sales of Provenge in the       prostate cancer drug market and does this agent have the potential to       become a blockbuster?   --  How will Provenge be used in the clinical setting and what hurdles is       it expected to face in its widespread uptake?   --  Will Dendreon pursue European approval of Provenge?   --  What are the market implications for other emerging therapeutic       vaccines in prostate cancer?    Dr. Merron will conduct a live Q & A session after the presentation.  

Members of the media who wish to attend this event can contact Christopher Comfort at 781-296-2597 or ccomfort@dresources.com to be registered for the session. Members of the media may also call Mr. Comfort if they wish to set up an interview with Dr. Merron prior to the analyst call on May 6.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Christopher Comfort   781-296-2597   ccomfort@dresources.com     /PRNewswire -- May 3/ 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

The Esophageal Cancer Drug Market in China Will Almost Double, Growing From $75 Million in 2009 to $149 Million in 2014

View Now